Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (11-20 of 186) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controlsFederico Innocenti, Mark J Ratain
Wiley Interdisciplinary Reviews. Systems Biology and Medicine|September 25, 2010
Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transportersDylan M Glubb, Federico Innocenti
Oncology (Williston Park, N.Y.)|June 13, 2003
Irinotecan treatment in cancer patients with UGT1A1 polymorphismsFederico Innocenti, Mark J Ratain
Therapeutic Drug Monitoring|May 29, 2007
Insights, challenges, and future directions in irinogeneticsTae Won Kim, Federico Innocenti
Clinical Advances in Hematology & Oncology : H&O|November 6, 2007
Translation of pharmacogenetic knowledge into cancer therapeuticsWei Peng Yong, Federico Innocenti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Individualizing dosing of irinotecanMark J Ratain, Federico Innocenti
Clinical Pharmacology and Therapeutics|June 5, 2004
"Irinogenetics" and UGT1A: from genotypes to haplotypesFederico Innocenti, Mark J Ratain
Pharmacogenomics|December 21, 2012
Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand?Dylan M Glubb, Federico Innocenti
Personalized Medicine|May 26, 2018
Role of UGT1A1*6 in irinogenetics in AsiansTae Won Kim, Federico Innocenti
Pharmacogenomics|December 23, 2006
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotypingFederico Innocenti, Mark J Ratain
Pageof 19

Showing results (11-20 of 186) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controlsFederico Innocenti, Mark J Ratain
Wiley Interdisciplinary Reviews. Systems Biology and Medicine|September 25, 2010
Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transportersDylan M Glubb, Federico Innocenti
Oncology (Williston Park, N.Y.)|June 13, 2003
Irinotecan treatment in cancer patients with UGT1A1 polymorphismsFederico Innocenti, Mark J Ratain
Therapeutic Drug Monitoring|May 29, 2007
Insights, challenges, and future directions in irinogeneticsTae Won Kim, Federico Innocenti
Clinical Advances in Hematology & Oncology : H&O|November 6, 2007
Translation of pharmacogenetic knowledge into cancer therapeuticsWei Peng Yong, Federico Innocenti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Individualizing dosing of irinotecanMark J Ratain, Federico Innocenti
Clinical Pharmacology and Therapeutics|June 5, 2004
"Irinogenetics" and UGT1A: from genotypes to haplotypesFederico Innocenti, Mark J Ratain
Pharmacogenomics|December 21, 2012
Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand?Dylan M Glubb, Federico Innocenti
Personalized Medicine|May 26, 2018
Role of UGT1A1*6 in irinogenetics in AsiansTae Won Kim, Federico Innocenti
Pharmacogenomics|December 23, 2006
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotypingFederico Innocenti, Mark J Ratain
Pageof 19